Talphera profit margin TLPH
Gross, operating and net profit as a share of revenue over the last twelve months, from 2013.
- Net margin, 12 months
- n/m
- not a meaningful number
- Peer median
- 3.3%
Talphera's net margin works out at −1507600% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.
Profit margin over time
GrossOperatingNet
Fiscal year by fiscal year
| Fiscal year | Net margin | Gross margin |
|---|---|---|
| FY2025 | n/a | n/a |
| FY2024 | n/a | n/a |
| FY2023 | n/a | n/a |
| FY2022 | n/a | n/a |
| FY2021 | n/a | −33.2% |
| FY2020 | n/a | −11.4% |
| FY2019 | n/a | n/a |
| FY2018 | n/a | −84.8% |
| FY2017 | n/a | −33.3% |
| FY2016 | n/a | 29.0% |
| FY2015 | n/a | n/a |
| FY2014 | n/a | n/a |
| FY2013 | −79.4% | n/a |
| FY2012 | n/a | n/a |
| FY2011 | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year |
|---|---|---|---|
| Q2 FY26 | n/a | n/a | |
| Q1 FY26 | n/a | n/a | |
| Q4 FY25 | n/a | n/a | |
| Q3 FY25 | n/a | n/a | |
| Q2 FY25 | n/a | n/a | |
| Q1 FY25 | n/a | n/a | |
| Q4 FY24 | n/a | n/a | |
| Q3 FY24 | n/a | n/a | |
| Q2 FY24 | n/a | n/a | |
| Q1 FY24 | n/a | n/a | |
| Q4 FY23 | n/a | n/a | |
| Q3 FY23 | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Talphera's size, closest first, today.
| Company | Profit margin |
|---|---|
| TLPHTalphera | n/m |
| SPROSpero Therapeutics | 15.7% |
| ATNMActinium Pharmaceuticals | n/m |
| LFVNLifevantage | 2.8% |
| NATRNatures Sunshine Products | 3.7% |
| ARVNArvinas | 2.9% |
| Peer median | 3.3% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Talphera
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.